Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark R Green

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Seminars in Oncology|August 10, 2002
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancerMark R Green
Clinical Lung Cancer|January 15, 2004
The evolving role of gemcitabine and pemetrexed (Alimta) in the management of patients with malignant mesotheliomaMark R Green
The New England Journal of Medicine|May 1, 2004
Targeting targeted therapyMark R Green
Lung Cancer (Amsterdam, Netherlands)|November 15, 2002
Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesotheliomaMark R Green
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancerMark R Green
Clinical Lung Cancer|May 1, 2004
Pemetrexed alone and in combination with platinum compounds in the management of malignant mesotheliomaHarit Suwanrusme, Mario L Meyer, Mark R Green
Seminars in Oncology|October 22, 2008
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group BMark R Green, Stephen L George, Richard L Schilsky, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group BHedy L Kindler, James E Herndon, Chunfeng Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)Antonius A Miller, James E Herndon, Lin Gu, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2004
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancerCarol A Sherman, James E Herndon, Dorothy M Watson, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Seminars in Oncology|August 10, 2002
Perspectives and opportunities: Docetaxel in the current and future treatment of non-small cell lung cancerMark R Green
Clinical Lung Cancer|January 15, 2004
The evolving role of gemcitabine and pemetrexed (Alimta) in the management of patients with malignant mesotheliomaMark R Green
The New England Journal of Medicine|May 1, 2004
Targeting targeted therapyMark R Green
Lung Cancer (Amsterdam, Netherlands)|November 15, 2002
Alimta (pemetrexed disodium): a multitargeted antifolate for the treatment of mesotheliomaMark R Green
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2008
Lessons from a time capsule: evolution, not revolution, in therapy for advanced non-small-cell lung cancerMark R Green
Clinical Lung Cancer|May 1, 2004
Pemetrexed alone and in combination with platinum compounds in the management of malignant mesotheliomaHarit Suwanrusme, Mario L Meyer, Mark R Green
Seminars in Oncology|October 22, 2008
Tomorrow's cancer treatments today: the first 50 years of the Cancer and Leukemia Group BMark R Green, Stephen L George, Richard L Schilsky, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group BHedy L Kindler, James E Herndon, Chunfeng Zhang, et al.
Lung Cancer (Amsterdam, Netherlands)|May 17, 2005
Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004)Antonius A Miller, James E Herndon, Lin Gu, et al.
Lung Cancer (Amsterdam, Netherlands)|August 11, 2004
A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancerCarol A Sherman, James E Herndon, Dorothy M Watson, et al.
Pageof 7